Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
Status:
Enrolling by invitation
Trial end date:
2024-12-19
Target enrollment:
Participant gender:
Summary
The rationale of the ROSY-O study is to continue to provide study treatment for patients who
have participated in a parent study with olaparib and who are continuing to derive clinical
benefit from treatment at the end of such studies, as judged by the Investigator.